PROQR THERAPEUTICS Shares Outstanding vs. Revenue
| 0PQ Stock | EUR 3.40 0.01 0.29% |
For PROQR THERAPEUTICS profitability analysis, we use financial ratios and fundamental drivers that measure the ability of PROQR THERAPEUTICS to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well PROQR THERAPEUTICS EO 04 utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between PROQR THERAPEUTICS's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of PROQR THERAPEUTICS EO 04 over time as well as its relative position and ranking within its peers.
PROQR |
PROQR THERAPEUTICS Revenue vs. Shares Outstanding Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining PROQR THERAPEUTICS's current stock value. Our valuation model uses many indicators to compare PROQR THERAPEUTICS value to that of its competitors to determine the firm's financial worth. PROQR THERAPEUTICS EO 04 is number one stock in shares outstanding category among its peers. It is rated third in revenue category among its peers totaling about 0.06 of Revenue per Shares Outstanding. The ratio of Shares Outstanding to Revenue for PROQR THERAPEUTICS EO 04 is roughly 18.16 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PROQR THERAPEUTICS's earnings, one of the primary drivers of an investment's value.PROQR Revenue vs. Shares Outstanding
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
PROQR THERAPEUTICS |
| = | 71.43 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
PROQR THERAPEUTICS |
| = | 3.93 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
PROQR Revenue vs Competition
PROQR THERAPEUTICS EO 04 is rated third in revenue category among its peers. Market size based on revenue of Biotechnology industry is presently estimated at about 42.73 Billion. PROQR THERAPEUTICS adds roughly 3.93 Million in revenue claiming only tiny portion of stocks in Biotechnology industry.
PROQR THERAPEUTICS Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in PROQR THERAPEUTICS, profitability is also one of the essential criteria for including it into their portfolios because, without profit, PROQR THERAPEUTICS will eventually generate negative long term returns. The profitability progress is the general direction of PROQR THERAPEUTICS's change in net profit over the period of time. It can combine multiple indicators of PROQR THERAPEUTICS, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands. PROQR THERAPEUTICS is traded on Frankfurt Stock Exchange in Germany.
PROQR Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on PROQR THERAPEUTICS. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of PROQR THERAPEUTICS position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the PROQR THERAPEUTICS's important profitability drivers and their relationship over time.
Use PROQR THERAPEUTICS in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if PROQR THERAPEUTICS position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PROQR THERAPEUTICS will appreciate offsetting losses from the drop in the long position's value.PROQR THERAPEUTICS Pair Trading
PROQR THERAPEUTICS EO 04 Pair Trading Analysis
The ability to find closely correlated positions to PROQR THERAPEUTICS could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PROQR THERAPEUTICS when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PROQR THERAPEUTICS - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PROQR THERAPEUTICS EO 04 to buy it.
The correlation of PROQR THERAPEUTICS is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PROQR THERAPEUTICS moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PROQR THERAPEUTICS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PROQR THERAPEUTICS can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your PROQR THERAPEUTICS position
In addition to having PROQR THERAPEUTICS in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Care ETFs Thematic Idea Now
Health Care ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Health Care ETFs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Care ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in PROQR Stock
To fully project PROQR THERAPEUTICS's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of PROQR THERAPEUTICS at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include PROQR THERAPEUTICS's income statement, its balance sheet, and the statement of cash flows.